<DOC>
	<DOC>NCT02291055</DOC>
	<brief_summary>Part A: (ADXS11-001 + MEDI4736 Combination Therapy) will determine the safety and tolerability of the combination and to identify a RP2D. Part B: Phase 2 design which will randomize subjects 1:1 to either MEDI4736 alone or MEDI4736+ADXS11-001 in subjects who have failed at least 1 prior systemic treatment for their recurrent/persistent or metastatic cervical cancer.</brief_summary>
	<brief_title>Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Have histological diagnosis of squamous cell cancer of the head &amp; neck with confirmation of HPV positivity or squamous, nonsquamous, adenosquamous, carcinoma or adenocarcinoma of the cervix which HPV positivity is not required 2. Have measurable and/or evaluable disease by RECIST 1.1 3. Have ECOG performance status of 0 or 1 4. Have adequate organ function defined by the protocol.: 1. Has any prior Grade â‰¥3 immunerelated adverse event (irAE) while receiving immunotherapy, including antiCTLA4 treatment, or any unresolved irAE &gt;Grade 1. 2. Has a diagnosis of immunodeficiency or is receiving any systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Day 1 of trial treatment. 3. Has any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for invasive malignancy within 2 years. Concurrent use of hormones for noncancerrelated conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable. 4. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. 5. Has implanted medical device(s) that pose a high risk for colonization and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous implant(s)). NOTE: More common devices and prosthetics which include arterial and venous stents, dental and breast implants, and venous access devices (e.g., PortaCath or Mediport) are permitted. Sponsor must be contacted prior to consenting any subject who has any other device and/or implant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>